Boardroom Alpha
Start trial
8-K primary document
SPRO · Current Report (Form 8-K) · Filed June 25, 2026

Spero Therapeutics Inc — 8-K exhibit

d86736dex31.htm
Spero Therapeutics Inc on Boardroom Alpha
EX-3.1

Exhibit 3.1

CERTIFICATE OF AMENDMENT

TO

RESTATED CERTIFICATE OF INCORPORATION

OF

SPERO THERAPEUTICS, INC.

It is hereby certified that:

 

FIRST:    The name of the corporation is Spero Therapeutics, Inc. (the “Corporation”).
SECOND:    The Amended and Restated Certificate of Incorporation of the Corporation, filed on August 17, 2021 (the “Restated Certificate of Incorporation”) is hereby further amended by striking out the first paragraph of the Fourth Article in its entirety and by substituting it with the following:

“FOURTH. The total number of shares of all classes of stock which the Corporation shall have authority to issue is 250,000,000 shares, consisting of 240,000,000 shares of Common Stock, $0.001 par value per share (the “Common Stock”) and 10,000,000 shares of Preferred Stock, $0.001 par value per share (the “Preferred Stock”).”

 

THIRD:      The amendment of the Amended and Restated Certificate of Incorporation herein certified has been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

EXECUTED, effective as of this 23rd day of June, 2026.

 

SPERO THERAPEUTICS, INC.
By:  

/s/ Esther Rajavelu

  Esther Rajavelu
  President and Chief Executive Officer
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer